Unresectable HCC with Extrahepatic Involvement
Unresectable HCC with Extrahepatic Involvement
A 77-Year-Old Male With Unresectable HCC and Extrahepatic Involvement
- History and physical exam
- An otherwise healthy, 77-year-old Caucasian male with a history of alcohol use
- Presented to his PCP complaining of abdominal pain, fatigue and an unexplained 10-lb weight loss
- Currently consumes 3-4 alcoholic drinks per day
- ECOG PS 0
- Imaging
- CT scan: 4.5-cm hepatic lesion with arterial hypervascularity, portal venous washout, and a pseudocapsule indicative of hepatocellular carcinoma; no evidence of vascular invasion
- Bone scan: left-sided iliac mass (3.1 cm)
- Chest CT: clear
- Diagnosis: unresectable HCC with extrahepatic involvement
- BCLC stage C
- Child-Pugh A
- AFP Level: 3548.4 ng/mL
- Weight: 72 kg
- Lenvatinib 12 mg QD was initiated.
- He experienced modest weight loss and reported loss of appetite for which he was referred for nutritional therapy
- Imaging at 16 weeks: partial response (0.5 cm)
- 8 months after initiation of therapy: treatment discontinued due to disease progression
Camrelizumab Plus Rivoceranib Maintains Survival Advantage in Untreated uHCC
June 2nd 2024With extended follow-up, the combination of investigational agents rivoceranib and camrelizumab demonstrated a significant survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.
Read More
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
April 28th 2024During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Read More
